Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous human polyclonal regulatory T cells
- Development stage
- Unknown
- Lead developer
- Shanghai Saierxin Biomedical Technology
- Modality
- Cell Therapies
- Administration
- Intrathecal
01
Overview
Autologous human polyclonal regulatory T cells (Tregs) are an adoptive cell therapy being developed for neurodegenerative and autoimmune diseases. This specific candidate, identified by the code NP001 and developed by Shanghai Saierxin Biomedical Technology (CellXen), consists of a patient's own Tregs that are isolated from peripheral blood, expanded ex vivo, and then re-administered. In the context of multiple system atrophy (MSA), NP001 is administered via intrathecal injection to directly target neuroinflammation within the central nervous system. The mechanism of action centers on the ability of Tregs to suppress the pro-inflammatory environment and microglial activation associated with alpha-synuclein aggregation, potentially slowing the progression of neurodegeneration and preserving neurological function in MSA patients.
- Other names
- autologous regulatory T cells
Beyond the preview
Go deeper on autologous human polyclonal regulatory T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous human polyclonal regulatory T cells.